

THEMATIC AREA: Pathogenesis.

<https://dx.doi.org/10.14482/sun.01.512.224>

ACV-2025-083

Markers of Inflammation, Tissue Damage, and Fibrosis in Individuals Diagnosed with Human Immunodeficiency Virus and Pneumonia: A Cohort Study

KATHERINE PEÑA-VALENCIA^{1,2,3}, WILL RIAÑO^{2,4}, MARIANA HERRERA-DÍAZ⁵,
LUCELLY LÓPEZ^{2,6}, DIANA MARÍN^{2,6}, SANDRA GONZALEZ^{5,7}, OLGA AGUDELO-GARCÍA³,
IVÁN ARTURO RODRÍGUEZ-SABOGAL^{4,8}, LÁZARO VÉLEZ⁸, ZULMA VANESSA RUEDA^{2,5},
YOAV KEYNAN^{5,9,10,11}

¹ Escuela de Microbiología, Universidad de Antioquia, Medellín (Colombia).

² Grupo de Investigación en Salud Pública, Facultad de Medicina, Universidad Pontificia Bolivariana, Medellín (Colombia).

³ Grupo Bacterias & Cáncer, School of Medicine, Universidad de Antioquia, Medellín (Colombia).

⁴ School of Medicine, Universidad de Antioquia, Medellín (Colombia).

⁵ Department of Medical Microbiology and Infectious Disease, University of Manitoba, Winnipeg (Canada).

⁶ School of Medicine, Universidad Pontificia Bolivariana, Medellín (Colombia).

⁷ JC Wilt Infectious Diseases Research Center, Winnipeg (Canada).

⁸ Infectious Diseases Section, Hospital Universitario San Vicente Fundación, Medellín (Colombia).

⁹ Grupo Investigador de Problemas en Enfermedades Infecciosas (GRIPE), Facultad de Medicina, Universidad de Antioquia, Medellín (Colombia).

¹⁰ Department of Internal Medicine, University of Manitoba, Winnipeg (Canada).

¹¹ Department of Community Health Sciences, University of Manitoba, Winnipeg (Canada).

Correspondence: Katherine Peña-Valencia. katherine.penav@udea.edu.co

ABSTRACT

Introduction: Previous studies have noted that persons living with human immunodeficiency virus (HIV) experience persistent lung dysfunction after an episode of community-acquired pneumonia (CAP), although the underlying mechanisms remain unclear. We hypothesized that inflammation during pneumonia triggers increased tissue damage and accelerated pulmonary fibrosis, resulting in a gradual loss of lung function.

Methods: We carried out a prospective cohort study of people diagnosed with CAP and/or HIV between 2016 and 2018 in three clinical institutions in Medellín, Colombia. Clinical data, blood samples, and pulmonary function tests (PFTs) were collected at baseline.

Results: Forty-one patients were included, divided into two groups: HIV and CAP ($n = 17$) and HIV alone ($n = 24$). We compared the concentrations of 17 molecules and PFT values between the groups. Notably, patients with HIV and pneumonia presented elevated levels of cytokines and chemokines (IL-6, IL-8, IL-18, IL-1RA, IL-10, IP-10, MCP-1, and MIP-1 β) compared to those with only HIV. A marked pulmonary dysfunction was evidenced by significant reductions in FEF25, FEF25-75, and FEV1. Moreover, the correlation between these immune mediators and lung function parameters supports the connection between pneumonia associated inflammation and end-organ lung dysfunction. A low CD4 cell count (< 200 cells/ μ L) predicted inflammation and lung dysfunction.

Conclusions: These results underscore the need for targeted clinical approaches to mitigate the adverse impacts of CAP on lung function in this population.

Keywords: inflammation, cytokines, pulmonary dysfunction, HIV, pneumonia.